外泌体在肝细胞癌中的作用及中药调控
肝细胞癌常发生于慢性肝脏炎症和肝硬化基础上,肝脏微环境对肿瘤发生发展至关重要。外泌体是纳米级膜囊泡,携带蛋白质、DNA和多种RNA,介导细胞间通讯并调控肿瘤微环境。本综述总结外泌体在肝细胞癌发生、进展和治疗中的作用,以及中药调控外泌体介导的肝细胞癌生物学行为的潜在价值。
要点
- 外泌体参与肝细胞癌与基质细胞通讯,调控增殖转移和免疫逃逸。
- 外泌体可作为肝细胞癌早期诊断标志物和药物递送载体。
- 中药可能调控外泌体释放及外泌体介导的细胞间通讯。
核心结论
- 外泌体参与肝细胞癌发生、进展和治疗,中药可能调控外泌体介导的肝细胞癌生物学行为。
研究设计与样本
- 综述,总结外泌体在肝细胞癌发生、进展和治疗中的最新进展及中药调控外泌体的潜在价值。
主要发现
- 外泌体携带蛋白质、DNA和多种RNA,介导细胞间通讯并调控肿瘤微环境。
- 外泌体参与肝细胞癌与内皮细胞、巨噬细胞、肝星状细胞和免疫细胞的通讯,调控肿瘤增殖、转移、免疫逃逸和免疫治疗。
- 外泌体可作为肝细胞癌早期诊断的特异性生物标志物和药物递送载体。
- 中药可能调控外泌体释放及外泌体介导的细胞间通讯。
临床怎么用
- 关注外泌体作为肝细胞癌早期诊断标志物和药物递送载体的潜在应用。
- 关注中药调控外泌体介导的肝细胞癌生物学行为的潜在价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatocellular carcinoma (HCC) usually occurs on the basis of chronic liver inflammatory diseases and cirrhosis. The liver microenvironment plays a vital role in the tumor initiation and progression. Exosomes, which are nanometer-sized membrane vesicles are secreted by a number of cell types. Exosomes carry multiple proteins, DNAs and various forms of RNA, and are mediators of cell-cell communication and regulate the tumor microenvironment. In the recent decade, many studies have demonstrated that exosomes are involved in the communication between HCC cells and the stromal cells, including endothelial cells, macrophages, hepatic stellate cells and the immune cells, and serve as a regulator in the tumor proliferation and metastasis, immune evasion and immunotherapy. In addition, exosomes can also be used for the diagnosis and treatment HCC. They can potentially serve as specific biomarkers for early diagnosis and drug delivery vehicles of HCC. Chinese herbal medicine, which is widely used in the prevention and treatment of HCC in China, may regulate the release of exosomes and exosomes-mediated intercellular communication. In this review, we summarized the latest progresses on the role of the exosomes in the initiation, progression and treatment of HCC and the potential value of Traditional Chinese medicine in exosomes-mediated biological behaviors of HCC.
引用
- Yao M, Liang S, Cheng B, et al. Role of exosomes in hepatocellular carcinoma and the regulation of traditional Chinese medicine. Front Pharmacol. 2023. PMID: 36733504. doi:10.3389/fphar.2023.1110922
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。